Genetic Predisposition to Disease Clinical Trial
Official title:
Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants (1U01TR003201-01A1)
This research study is exploring the use of genomic sequencing in the newborn period to screen healthy babies for current and future health risks. The study will enroll a diverse cohort of 500 healthy infants and their parents from Boston, MA; New York City, NY; and Birmingham, AL. A small blood sample will be collected from each infant, and whole genome sequencing will be performed in 1/2 of the cohort following a randomized controlled trial design. 3 months later, the randomization status and sequencing results will be shared with parents and pediatricians. Investigators will study the medical, behavioral, and economic outcomes of genomic sequencing to better understand how this technology can be implemented in outpatient primary care settings.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | July 1, 2025 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 0 Months to 12 Months |
Eligibility | Inclusion Criteria: Infant participants - Has not previously had exome or genome sequencing - Age 0-12 months - Seen for well-baby pediatric care at a recruiting site - Primary healthcare provider completed the genomics education program - At least one parent or guardian able to participate in the study Parent participants - Biological parent or legal guardian of an infant participating in the study - 18 years of age or older - Unimpaired decision-making capacity - English or Spanish speaking - Available to have genetic counseling and provide consent for testing the infant Exclusion Criteria: - Parents are unwilling to have genomic reports placed in the medical record or sent to their primary care pediatrician - Any infant in which clinical considerations preclude collecting blood via heel stick |
Country | Name | City | State |
---|---|---|---|
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | Beaumont - Corewell Health East | Royal Oak | Michigan |
Lead Sponsor | Collaborator |
---|---|
Brigham and Women's Hospital | Baylor College of Medicine, Boston Children's Hospital, Broad Institute, Dartmouth-Hitchcock Medical Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Harvard Pilgrim Health Care, Howard University, HudsonAlpha Institute for Biotechnology, Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, National Center for Advancing Translational Sciences (NCATS), University of Alabama at Birmingham |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | MDR-associated intervention | Healthcare intervention prompted by monogenic disease risk or recessive carrier variant | 1-year post-disclosure (15 months after enrollment) | |
Other | Suspected genetic condition | Any phenotype that develops in an infant suspected to have a genetic cause, or any genetic testing ordered as part of clinical care | 1-year post-disclosure (15 months after enrollment) | |
Other | Cost of attributable services | Cost of healthcare services that were recommended for infants and parents as part of study disclosure session | 1-year post-disclosure (15 months after enrollment) | |
Other | Cost of genomic services | Cost of genetic services infants and parents received after study disclosure session | 1-year post-disclosure (15 months after enrollment) | |
Other | All healthcare costs | All health sector costs observed in medical records and survey questions regarding family out-of-pocket expenses | 1-year post-disclosure (15 months after enrollment) | |
Primary | Monogenic disease risks (MDRs) | Pathogenic (P) and likely pathogenic (LP) variants identified relevant to infant's health (dominant or biallelic recessive disease risks) | 3 months after enrollment | |
Primary | Carrier status variants | P and LP variants identified as recessive carrier status in infant | 3 months after enrollment | |
Primary | MDR-associated phenotype | Signs or symptoms of monogenic disease risk identified by genome sequencing | 3 months after enrollment and 1-year post-disclosure (15 months after enrollment) | |
Primary | Parent-Child Relationship | Parenting Stress Index, 4th Edition Short Form (scored as a percentile 0 - 100%, higher scores indicate increased stress); Vulnerable Baby Scale (scored 0 -50, higher scores indicate increased perceptions of child vulnerability) | Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment) | |
Primary | Partner Relationship | Kansas Marital Satisfaction Scale (Scored 3 to 21, higher scores indicate better marital quality; Partner Blame (novel, higher scores indicate increased blame) | Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment) | |
Primary | Personal Distress | General Anxiety Disorder-7, Patient Health Questionnaire (PHQ)-9 , Self-Blame | Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment) | |
Secondary | MDR-associated family history | Signs or symptoms of monogenic disease risk or recessive condition present in infant's biological family | 3 months after enrollment and 1-year post-disclosure (15 months after enrollment) | |
Secondary | Feelings about genomic testing | Feelings About genomiC Testing Results (FACToR) Questionnaire | Baseline, post-disclosure (3 months after enrollment), 6 months post-disclosure (9 months after enrollment) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05020574 -
Microbiome and Association With Implant Infections
|
Phase 2 | |
Recruiting |
NCT06057181 -
Helix Research Network
|
||
Recruiting |
NCT04390269 -
Immunogenetics Predictors With COVID-19
|
||
Recruiting |
NCT04427163 -
Assesment of Multiomics Profiles in Health and Disease.
|
||
Completed |
NCT03597659 -
PheWAS of a Polygenic Predictor of Thyroid Function
|
||
Active, not recruiting |
NCT04634032 -
Gene Expression and DNA Variation Analysis of Sacs to Identify the Pathophysiology of Indirect Inguinal Hernia
|
||
Completed |
NCT04145817 -
Breast Cancer Risk After Diagnostic Gene Sequencing
|
N/A | |
Recruiting |
NCT04600544 -
Russian Disc Degeneration Study
|
||
Not yet recruiting |
NCT04788927 -
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
|
||
Not yet recruiting |
NCT03234140 -
Constitutional Genetics in Follicular Lymphoma
|
N/A | |
Completed |
NCT01973075 -
Genetic Etiology in Premature Ovarian Insufficiency
|
N/A | |
Completed |
NCT00555503 -
Registry of Mastectomy for Breast Cancer Risk Reduction
|
N/A | |
Active, not recruiting |
NCT05524909 -
Full-scale Intervention Study: Genetic Risk Communication and Wearables
|
N/A | |
Suspended |
NCT04151368 -
Surgical and Patient Reported Outcomes of Robotic Nipple-Sparing Mastectomy
|
N/A | |
Completed |
NCT02422511 -
Genomic Sequencing for Childhood Risk and Newborn Illness
|
N/A | |
Completed |
NCT00677495 -
Gluten-free Diet in Gluten-genetically Predisposed Subjects
|
N/A | |
Recruiting |
NCT05759143 -
Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing
|
N/A | |
Enrolling by invitation |
NCT05721326 -
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
|
N/A | |
Active, not recruiting |
NCT05685810 -
Genetic Determinants of Kidney Disease in People of African Ancestry With HIV
|
||
Recruiting |
NCT04903782 -
Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer
|